Impact of tisagenlecleucel product attributes on clinical outcomes in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL).

被引：0
|
作者：
Gershgorin, Irina [1 ]
Waldron, Edward R. [1 ]
Grupp, Stephan A. [2 ]
Levine, John E. [3 ]
Pulsipher, Michael A. [4 ]
Davies, Stella M. [5 ]
Myers, G. Doug [6 ]
Jeschke, Margit [7 ]
Engels, Boris [8 ]
del Corral, Chris [1 ]
Baruchel, Andre [9 ,10 ]
机构：
[1] Novartis Pharmaceut, E Hanover, NJ USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Childrens Hosp Los Angeles, Keck Sch Med USC, Los Angeles, CA 90027 USA
[5] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[6] Childrens Mercy Hosp, Kansas City, MO 64108 USA
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Inst BioMed Res, Cambridge, MA USA
[9] Hop Univ Robert Debre, AP HP, Paris, France
[10] Univ Paris, Paris, France
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
510
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results
    Rouce, Rayne H.
    Baumeister, Susanne H. C.
    Curran, Kevin J.
    Fabrizio, Vanessa A.
    Hall, Erin M.
    Hsieh, Emily M.
    Karras, Nicole A.
    Keating, Amy K.
    Moskop, Amy
    Pasquini, Marcelo C.
    Phillips, Christine L.
    Pulsipher, Michael A.
    Nuortti, Marja
    Willert, Jennifer
    Ramos, Roberto
    John, Samuel
    Grupp, Stephan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Evolution of Tisagenlecleucel Use for the Treatment of Pediatric and Young Adult Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) Registry Results
    Rouce, Rayne H.
    Baumeister, Susanne H. C.
    Curran, Kevin J.
    Fabrizio, Vanessa A.
    Hall, Erin M.
    Hsieh, Emily M.
    Karras, Nicole A.
    Keating, Amy K.
    Moskop, Amy
    Pasquini, Marcelo C.
    Phillips, Christine L.
    Pulsipher, Michael A.
    Nuortti, Marja
    Willert, Jennifer
    Ramos, Roberto
    John, Samuel
    Grupp, Stephan A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S261 - S262
  • [23] Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia
    Ma, Qiufei
    Zhang, Jie
    O'Brien, Elliott
    Martin, Amber L.
    Agostinho, Andrea Chassot
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (12) : 849 - 860
  • [24] Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective
    Yang, Hongbo
    Hao, Yanni
    Qi, Cynthia Z.
    Chai, Xinglei
    Wu, Eric Q.
    BLOOD, 2019, 134
  • [25] Venetoclax Combined With Chemotherapy in Pediatric and Adolescent/Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
    Place, Andrew E.
    Karol, Seth E.
    Forlenza, Christopher J.
    Cooper, Todd M.
    Fraser, Christopher
    Cario, Gunnar
    O'Brien, Maureen M.
    Gerber, Nicolas U.
    Bourquin, Jean-Pierre
    Reinhardt, Dirk
    Rubnitz, Jeffrey E.
    Opferman, Joseph T.
    Sunkersett, Gauri
    Onishi, Maika
    Dunshee, Diana R.
    Chen, Xin
    Unnebrink, Kristina
    Vishwamitra, Deeksha
    Dunbar, Fengjiao
    Badawi, Mohamed
    Ross, Jeremy A.
    Loh, Mignon L.
    PEDIATRIC BLOOD & CANCER, 2025,
  • [26] BUDGET IMPACT ANALYSIS ON BLINATUMOMAB FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R BCP-ALL)
    Zhao, J.
    Jin, G.
    Yang, L.
    VALUE IN HEALTH, 2022, 25 (07) : S404 - S405
  • [27] More Updates to Come of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial: Could the Statistical Methodology Be Further Improved?
    Tong, Wing H.
    Mertens, Bart J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (13) : 2450 - 2451
  • [28] Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Jabbour, Elias
    Roberts, Kathryn G.
    Sasaki, Koji
    Zhao, Yaqi
    Qu, Chunxu
    Gu, Zhaohui
    Jain, Nitin
    Patel, Keyur P.
    Ravandi, Farhad
    Short, Nicholas J.
    Garcia-Manero, Guillermo
    Garris, Rebecca
    Kornblau, Steven
    Konopleva, Marina Y.
    Mullighan, Charles G.
    Kantarjian, Hagop M.
    BLOOD, 2019, 134
  • [29] INFLUENCE OF BASELINE FACTORS ON OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) TREATED WITH BLINATUMOMAB
    Topp, M. S.
    Goekbuget, N.
    O'Brien, S.
    Stein, A.
    Jia, C.
    Forman, S. J.
    Bargou, R.
    Fielding, A. K.
    Heffner, L. T., Jr.
    Larson, R. A.
    Neumann, S.
    Maniar, T.
    Nagorsen, D.
    Kantarjian, H.
    HAEMATOLOGICA, 2015, 100 : 30 - 30
  • [30] Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome-positive (Ph plus ) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
    Stock, Wendy
    Martinelli, Giovanni
    Stelljes, Matthias
    DeAngelo, Daniel J.
    Gokbuget, Nicola
    Advani, Anjali S.
    O'Brien, Susan Mary
    Liedtke, Michaela
    Merchant, Akil Abid
    Cassaday, Ryan Daniel
    Wang, Tao
    Vandendries, Erik
    Marks, David I.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345